Unless RAC have spoken to the FDA a few times & know exactly...

Unless RAC have spoken to the FDA a few times & know exactly what they are after to be able to approve em off early P2 data in 2026.

Id imagine you’d need to have something that either helped rare, late stage patients without many options, as an example patients that have failed multiple prior lines of treatment. Or potentially have something with Dual MOA that had anti cancer & cardioprotective qualities. Or acted as an FTO inhibitor and had synergy between multiple approved treatments. Most of which are close to patient cliffs.

Im not sure who would come first, the FDA or BP.
Mid 2026 will be very interesting if we make it that far (as long as everything stays on track)

I’d be shocked if we were still here in 2029 and weren’t at least sitting on 10-20x at a minimum.
id also only be 39yrs old so i can wait to be shocked.